1 / 12

Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase

Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Ari Robicsek, Jacob Strahilevitz, George A Jacoby Nature Medicine 12 , 1,January (2006) Infection disease 林建州 報告. Background. Peperazinyl substituent. AIM.

Download Presentation

Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase Ari Robicsek, Jacob Strahilevitz, George A Jacoby Nature Medicine12, 1,January (2006) Infection disease 林建州 報告

  2. Background Peperazinyl substituent

  3. AIM Identification of a variant of an aminoglycoside-modifying enzyme, that has acquired the ability also to modify select fluoroquinolones

  4. Result • Identification of the resistance gene • Gene cloning and screening • Site –directed mutagenesis • Chemical deternination of the mechanism of resistance • Phenotypic testing • Determination of resistance-promoting potential • Population screening

  5. Integron sequence of plasmid pHSH10-2. Encoded quinolone resistance gene

  6. 4X

  7. Transformation Low level ciprofloxacin resistance

  8. Figure 1.Sequence alignment of eight different aac(6')-Ib variants and aac(6')-Ib-cr. Try102 Arg, Asp179Try

  9. Figure 2.Enzyme kinetics of AAC(6')-Ib-cr. Ecoli DH10B Acetyl transferase activity

  10. E. coli J53 pBC SK-aac(6')-Ib-cr (. ) Figure3.Mutant prevention concentration (MPC) assay. E. coli J53 (o )

  11. Summary • We describe reduced susceptibility to ciprofloxacin in clinical bacterial isolates conferred by a variant of the gene encoding aminoglycoside acetyltransferase AAC(6')-Ib. • This enzyme reduces the activity of ciprofloxacin by N-acetylation at the amino nitrogen on its piperazinyl substituent • a single-function resistance enzyme has crossed class boundaries, and is now capable of enzymatically undermining two unrelated antimicrobial agents, one of them fully synthetic.

More Related